All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Pieter Sonneveld, Erasmus MC, Rotterdam, NL. We asked, Why the initial efficacy observed with melflufen + dexamethasone has not translated into improved overall survival (OS) in the OCEAN phase III trial.
OCEAN phase III trial: Why the initial efficacy observed with melflufen + dex has not improved OS
Your opinion matters
How to diagnose and treat high-risk multiple myeloma after EHA 2020
Interview with Pieter Sonneveld, Erasmus MC, Rotterdam, NL, who discussed the diagnosis and treatment of high-risk MM after EHA 2020.
Priority Review of melflufen for patients with triple-class refractory MM by FDA
The first-in-class peptide–drug conjugate melphalan flufenamide, also known as melflufen (MF), in combination with dexamethasone is to receive priority review by the...
Subscribe to get the best content related to multiple myeloma delivered to your inbox